Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report sent to investors on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

Brainstorm Cell Therapeutics stock opened at $0.43 on Wednesday. The stock has a market capitalization of $29.39 million, a price-to-earnings ratio of -1.05 and a beta of 0.40. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and a 52-week high of $3.34. The stock’s 50 day moving average price is $0.49 and its two-hundred day moving average price is $0.35.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its earnings results on Monday, April 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. On average, equities research analysts forecast that Brainstorm Cell Therapeutics will post -0.28 EPS for the current year.

Institutional Trading of Brainstorm Cell Therapeutics

An institutional investor recently bought a new position in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 14.33% of the company’s stock.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.